Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 569

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 569
---
2024, restructuring expenses were $5.7 million which were related to Cara’s strategic prioritization of NP in January 2024 and the resulting discontinuation of Cara’s NP program in June 2024, Cara’s exploration of strategic alternatives to maximize shareholder value, and the associated workforce reductions during the year. There were no restructuring expenses recorded during the nine months ended September 30, 2023. Other Income, Net**

| ​                 
 ​                 
 ​                 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months EndedSeptember 30, 
 2024                            
 Dollar amounts in thousands     |   |     |   | ​ | ​ | 2023 |   |     |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​    
 ​    | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 Dollar amounts in thousands    |   |       |   | ​ | ​ | 2023 |   |       |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​    
 ​    | ​ 
 ​ | ​ 
 ​ 
 ​ |
|:------------------|:--|:--|:--------------------------------|:--|----:|:--|:--|:--|:-----|:--|----:|:--|:--|:--|:---------|:--|:-----|:--|:--|:--|:-------------------------------|:--|------:|:--|:--|:--|:-----|:--|------:|:--|:--|:--|:---------|:--|:-----|:--|:--|
| Other income, net | ​ | ​ | ​                               | $ | 766 | ​ | ​ | ​ | ​    | $ | 866 | ​ | ​ | ​ | ​        | ​ | -12% | ​ | ​ | ​ | ​                              | $ | 2,407 | ​ | ​ | ​ | ​    | $ | 2,712 | ​ | ​ | ​ | ​        | ​ | -11% | ​ | ​ |

**For the three months ended September 30, 2024 compared to the three months ended September 30, 2023, the decrease in